NASDAQ:SPNE

SeaSpine Competitors

$21.94
-0.47 (-2.10 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.65
Now: $21.94
$22.97
50-Day Range
$17.19
MA: $18.76
$22.41
52-Week Range
$8.04
Now: $21.94
$22.97
Volume200,415 shs
Average Volume114,457 shs
Market Capitalization$612.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

Competitors

SeaSpine (NASDAQ:SPNE) Vs. INO, GNMK, SILK, ATEC, LMNX, and LUNG

Should you be buying SPNE stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to SeaSpine, including Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Silk Road Medical (SILK), Alphatec (ATEC), Luminex (LMNX), and Pulmonx (LUNG).

SeaSpine (NASDAQ:SPNE) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Inovio Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
Inovio Pharmaceuticals$4.11 million441.95$-119,360,000.00($1.16)-7.52

SeaSpine has higher revenue and earnings than Inovio Pharmaceuticals. SeaSpine is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Inovio Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
Inovio Pharmaceuticals14302.25

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Inovio Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 94.95%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Summary

SeaSpine beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 3.3% of GenMark Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and GenMark Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26

SeaSpine has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and GenMark Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
GenMark Diagnostics05002.00

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. GenMark Diagnostics has a consensus price target of $22.0125, indicating a potential downside of 8.24%. Given SeaSpine's stronger consensus rating and higher possible upside, research analysts clearly believe SeaSpine is more favorable than GenMark Diagnostics.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and GenMark Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
GenMark Diagnostics-16.95%-39.36%-13.02%

Summary

SeaSpine beats GenMark Diagnostics on 8 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 7.8% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Silk Road Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
Silk Road Medical$63.35 million27.20$-52,420,000.00($1.36)-36.87

SeaSpine has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Silk Road Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
Silk Road Medical02202.50

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Silk Road Medical has a consensus price target of $61.75, indicating a potential upside of 23.16%. Given Silk Road Medical's higher possible upside, analysts clearly believe Silk Road Medical is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
Silk Road Medical-53.66%-40.79%-24.56%

Summary

SeaSpine beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Alphatec's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
Alphatec$113.43 million14.76$-57,000,000.00($1.09)-16.15

SeaSpine has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Alphatec, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
Alphatec00703.00

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Alphatec has a consensus price target of $15.4286, indicating a potential downside of 12.34%. Given SeaSpine's higher possible upside, research analysts clearly believe SeaSpine is more favorable than Alphatec.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
Alphatec-51.95%-266.45%-40.80%

Summary

SeaSpine beats Alphatec on 8 of the 13 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 9.4% of Luminex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Luminex's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90

Luminex has higher revenue and earnings than SeaSpine. Luminex is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Luminex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
Luminex00103.00

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Luminex has a consensus price target of $38.00, indicating a potential upside of 15.33%. Given Luminex's higher possible upside, analysts clearly believe Luminex is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares SeaSpine and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
Luminex4.60%3.75%2.73%

Summary

Luminex beats SeaSpine on 10 of the 13 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Pulmonx's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeaSpine$159.08 million3.85$-39,280,000.00($2.07)-10.60
Pulmonx$32.60 million47.60$-20,700,000.00N/AN/A

Pulmonx has lower revenue, but higher earnings than SeaSpine.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Pulmonx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SeaSpine00603.00
Pulmonx03502.63

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Pulmonx has a consensus price target of $58.00, indicating a potential upside of 33.39%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than SeaSpine.

Profitability

This table compares SeaSpine and Pulmonx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeaSpine-27.32%-24.38%-19.64%
PulmonxN/AN/AN/A

Summary

Pulmonx beats SeaSpine on 6 of the 11 factors compared between the two stocks.

pixel
Ad True Market Insiders
April 30th is approaching, are you prepared?
A new president’s policies always influence key stocks.

SeaSpine Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72-0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14-0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60-1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95-2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48-4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
Soliton logo
SOLY
Soliton
1.1$18.25-0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90-0.2%$385.05 million$24.95 million-26.97News Coverage
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73-0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20-0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50-3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79-2.5%$324.97 million$62.66 million-7.61Gap Up
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54-1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62-3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04-3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10-2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53-0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82-7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72-0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96-3.6%$159.59 millionN/A-34.80Gap Up
PolyPid logo
PYPD
PolyPid
1.4$9.33-2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44-0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66-1.1%$147.07 million$50.71 million-4.56Gap Up
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20-1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50-0.7%$142.95 million$9.13 million-1.15News Coverage
Gap Up
Beyond Air logo
XAIR
Beyond Air
1.7$5.95-1.8%$121.90 million$1.39 million-3.79
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.